Rapport Therapeutics, Inc. Common Stock - Asset Resilience Ratio
Rapport Therapeutics, Inc. Common Stock (RAPP) has an Asset Resilience Ratio of 80.13% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2022–2025)
This chart shows how Rapport Therapeutics, Inc. Common Stock's Asset Resilience Ratio has changed over time. See Rapport Therapeutics, Inc. Common Stock leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.
Liquid Assets Composition Over Time
This chart breaks down Rapport Therapeutics, Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Rapport Therapeutics, Inc. Common Stock (RAPP) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $398.73 Million | 80.13% |
| Total Liquid Assets | $398.73 Million | 80.13% |
Asset Resilience Insights
- Very High Liquidity: Rapport Therapeutics, Inc. Common Stock maintains exceptional liquid asset reserves at 80.13% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Rapport Therapeutics, Inc. Common Stock Industry Peers by Asset Resilience Ratio
Compare Rapport Therapeutics, Inc. Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Prostemics Co. Ltd
KQ:203690 |
Biotechnology | 0.31% |
|
ORUM
KQ:475830 |
Biotechnology | 82.74% |
|
TELIX Pharmaceuticals Ltd
AU:TLX |
Biotechnology | 32.29% |
|
TG Therapeutics Inc
NASDAQ:TGTX |
Biotechnology | 4.72% |
|
Green Cross Holdings Preference Shares
KO:005257 |
Biotechnology | 0.50% |
|
Rocket Pharmaceuticals Inc
NASDAQ:RCKT |
Biotechnology | 33.70% |
|
NEWRON PHARMACEUT. EO-20
XETRA:NP5 |
Biotechnology | 41.67% |
|
Cybin Inc
NEO:CYBN |
Biotechnology | 0.21% |
Annual Asset Resilience Ratio for Rapport Therapeutics, Inc. Common Stock (2022–2025)
The table below shows the annual Asset Resilience Ratio data for Rapport Therapeutics, Inc. Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 85.45% | $437.89 Million | $512.43 Million | +6.56pp |
| 2024-12-31 | 78.90% | $248.47 Million | $314.93 Million | +29.16pp |
| 2023-12-31 | 49.74% | $77.31 Million | $155.42 Million | -- |
| 2022-12-31 | 0.00% | $0.00 | $31.60 Million | -- |
About Rapport Therapeutics, Inc. Common Stock
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containin… Read more